Alta Partners

Alta Partners
Type	Private ownership
Industry	Private equity
Predecessor	Burr, Egan, Deleage & Co.
Founded	1996
Founder	Dr. Jean Deleage, Ph.D., Garrett Gruener, Marino Polestra, Guy Paul Nohra
Headquarters	One Embarcadero Center; San Francisco, California, United States
Products	Venture capital
Website	www.altapartners.com

Alta Partners is a venture capital firm based in San Francisco which invests primarily in biotechnology and life science companies.

History[]

The company was founded in 1996 by Dr. Jean Deleage, Ph.D., who was also a founder of the venture capital firms Burr, Egan, Deleage & Co. (BEDCO) and Sofinnova, together with Guy Paul Nohra, Marino Polestra, and Garrett Gruener, all former general partners at BEDCO.^{[citation needed]}

Alta Partners is actively investing out of its latest early stage fund called Alta Nextgen II by managing directors Dan Janney, Pete Hudson, MD, and Bob More. Co founders Jean Deleage and Marino Polestra have died while Garrett Gruener is retired. Guy Nohra is currently managing Alta Spain I out of Barcelona Spain.

The company was founded in 1996 and invests in biotechnology and life science companies. According to the company website, over the past 22 years, Alta has invested in over 150 companies, including some of the leaders in the biopharmaceuticals, medical technology, healthcare services, and information technology sectors.^{[citation needed]}

The firm is no longer associated with the Boston-based venture capital firms, Alta Communications, or Polaris ventures which also trace their roots to Burr, Egan, Deleage & Co.

Investment funds[]

Since 1996, Alta has raised nine venture capital funds including four funds in its Alta California Funds series, three funds in its Alta Biopharma Partners series, Alta Partners VIII, and most recently Alta Partners NextGen Fund I with $130 million of investor commitments.^{[citation needed]}

The following is a summary of the venture capital funds raised by Alta as of 2018:

1996 - $130m - Alta California Partners (Early Stage)
1998 - $180m - Alta Biopharma Partners I (Late Stage)
1998 - $186m - Alta California Partners II (Early Stage)
2000 - $212m - Alta Biopharma Partners II
2000 - $229m - Alta California Partners III (Early Stage)
2003 - $300m - Alta BioPharma Partners III
2004 - $184m - Alta California Partners IV (Early Stage)
2006 - $500m - Alta Partners VIII
2017 - $130m - Alta Partners NextGen Fund I (Early Stage)
2019 - $150m - Alta Partners NextGen Fund II (Early Stage)

Investments[]

Notable investments include, Kite Pharmaceuticals, ZS Pharma, Esperion, Allakos Chemgenx, DeCode Calistoga, Aerie, Cymabay, Tyra Biosciences.^[1] For a full list of investments please go to Alta’s Web site.

References[]

^ "Carlsbad's Tyra Biosciences nets $50 million to combat drug resistance in cancer therapies". San Diego Union-Tribune. 2020-01-21. Retrieved 2020-04-23.

Gupta, Udayan. Done Deals: Venture Capitalists Tell Their Stories, 2000
Venture-Capital Firms Prepare for Next Generation of Partners
Jean Deleage (Forbes Profile)

External links[]

Alta Partners (company website)
Company profile at BioSpace

[1] "Carlsbad's Tyra Biosciences nets $50 million to combat drug resistance in cancer therapies". San Diego Union-Tribune. 2020-01-21. Retrieved 2020-04-23.

[1]

hide v t Private equity and venture capital investment firms
Investment strategy	Venture Growth Mezzanine Secondaries Leveraged buyout
History	History of private equity and venture capital Early history of private equity Private equity in the 1980s Private equity in the 1990s Private equity in the 2000s
Investors	Angel investor Commercial bank Corporate venture capital Crowdfunding Family office Endowment Fund of funds High-net-worth individual Institutional investor Insurance company Investment bank Merchant bank Pension fund Sovereign wealth fund
Private equity firms Venture capital firms Portfolio companies